Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05177328 · ClinicalTrials.gov registry record · Phase 1
Targeted Investigation of Microbiome Elimination
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT05177328 is a Phase 1 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 21 participants.
The verdict
NCT05177328, a Phase 1 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the pharmacokinetics or survival of new product containing commensal infection fighting bacteria, on the skin of patients with Atopic Dermatitis (AD), after a single application.
Interventions
- DRUG Placebo
- BIOLOGICAL S. hominis A 9 Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-07-18 |
| Est. Completion | 2023-10-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05177328
The ClinicalTrials.gov registry entry for NCT05177328 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05177328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05177328 about?
NCT05177328 is a clinical study titled "Targeted Investigation of Microbiome Elimination". The purpose of this study is to examine the pharmacokinetics or survival of new product containing commensal infection fighting bacteria, on the skin of patients with Atopic Dermatitis (AD), after a single application.
What is the current status of trial NCT05177328?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2022-07-18. Estimated completion is 2023-10-13.
What interventions are being tested in trial NCT05177328?
The interventions under investigation include: Placebo (DRUG), S. hominis A 9 Product (BIOLOGICAL).
Who is sponsoring clinical trial NCT05177328?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.